Integra Capital is a non-banking financial company that manages a portfolio of equity and debt securities while providing investment advisory and project management services to clients.
The company lacks a durable competitive advantage, as evidenced by its negative average net margins and low returns on capital. Its performance is entirely dependent on broader stock market movements rather than proprietary financial products or cost advantages.
Capital is primarily deployed into a trading portfolio of listed Indian equities and mutual funds. The company does not pay dividends and has a track record of low returns on equity, suggesting reinvestment is not creating significant shareholder value.
Five years out, the company has effectively become a stagnant pool of trapped capital. By operating as little more than a leveraged bet on the Indian equity market without proprietary edge, the firm suffered as the broader market entered a secular downturn. Management continued to extract high compensation relative to meager profits while related-party transactions leaked value to affiliates. With no operational cash flow to buffer against fair-value losses and a total lack of pricing power, the book value eroded steadily, leaving shareholders with a shell company that trades at a permanent discount to its dwindling assets.
RichFakir rates Integra Capital Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Integra Capital Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Integra Capital Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Integra Capital Ltd's fair value is about ₹5 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →